UBX - Unity Biotechnology, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
8.74
0.00 (0.00%)
At close: 4:00PM EDT

8.70 -0.04 (-0.46%)
After hours: 4:44PM EDT

Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Fast Stochastic

Fast Stochastic

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close8.74
Open8.53
Bid8.67 x 900
Ask8.73 x 800
Day's Range8.53 - 9.10
52 Week Range4.62 - 10.38
Volume276,919
Avg. Volume259,956
Market Cap429.511M
Beta (5Y Monthly)0.35
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More
    Benzinga

    The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More

    Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 2) * Forty Seven Inc (NASDAQ: FTSV)( announced a deal to be bought by Gilead Sciences, Inc. (NASDAQ: GILD)) * IGM Biosciences Inc (NASDAQ: IGMS) * Iovance Biotherapeutics Inc (NASDAQ: IOVA) * Karyopharm Therapeutics Inc (NASDAQ: KPTI)(announced positive late-stage results for selinexor) * Passage Bio Inc (NASDAQ: PASG)(IPOed Friday) * Syneos Health Inc (NASDAQ: SYNH) * Trillium Therapeutics Inc (NASDAQ: TRIL)(moved in sympathy with Forty Seven, as it has a similar drug in the pipeline for solid tumor) * Zynex Inc. (NASDAQ: ZYXI)Down In The Dumps (Biotech Stocks Hitting 52-week lows on March 2) * Aerie Pharmaceuticals Inc (NASDAQ: AERI) * AEterna Zentaris Inc. (NASDAQ: AEZS) * Akorn, Inc. (NASDAQ: AKRX) * ANI Pharmaceuticals Inc (NASDAQ: ANIP)(moved lower despite FDA nod for a generic version of Teva Pharmaceutical Industries Ltd's (NYSE: TEVA) Alzheimer's related dementia drug) * Autolus Therapeutics Ltd - ADR (NASDAQ: AUTL) * Axovant Gene Therapies Ltd (NASDAQ: AXGT) * Black Diamond Therapeutics Inc (NASDAQ: BDTX) * Eagle Pharmaceuticals Inc (NASDAQ: EGRX) (reacted to its fourth-quarter results) * Evolus Inc (NASDAQ: EOLS) * EXACT Sciences Corporation (NASDAQ: EXAS) * GenMark Diagnostics, Inc (NASDAQ: GNMK) * Imv Inc (NASDAQ: IMV) * Neurometrix Inc (NASDAQ: NURO) * Portola Pharmaceuticals Inc (NASDAQ: PTLA) * Precigen Inc (NASDAQ: PGEN) * Taro Pharmaceutical Industries Ltd. (NYSE: TARO) * Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) * TherapeuticsMD Inc (NASDAQ: TXMD) * Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) * Viking Therapeutics Inc (NASDAQ: VKTX)Related Link: How The COVID-19 Outbreak Is Benefiting Biotech InvestorsStocks In Focus GenMark Starts Shipping COVID-19 Test Kits GenMark said it has begun shipping ePlex Research Use Only, or RUO, test kits to detect COVID-19 virus. The initial shipment will go to its Hong Kong distributor as well as several U.S. customers having access to clinical samples.Separately, the company reported fourth-quarter results, showing 24% year-over-year revenue growth and a narrower loss of 17 cents per share, while analysts estimated a loss of 16 cents per share.The stock jumped 21.65% to $4.27 in after-hours trading.Novartis' Sandoz Unit Agrees For $195M Settlement In Generics Price Fixing Probe Novartis AG's (NYSE: NVS) Sandoz unit said it has reached a resolution with the U.S. DoJ in a 3-year-long antitrust investigation carried out by the agency into the U.S. generic drug industry. Sandoz said the settlement pertains to instances of misconduct by the company between 2013 and 2015 with certain generic drugs sold in the U.S. As part of the agreement, Sandoz will pay $195 million.Unity Biotech Taps Former Biogen Executive as CEO Unity Biotechnology Inc (NASDAQ: UBX) announced the appointment of Anirvan Ghosh as CEO and member of the board, effective March 30. Ghosh was previously with as Biogen Inc (NASDAQ: BIIB) as SVP, Head of Research and Early Development.The company said current CEO Keith Leonard will step down from the role due to personal circumstances.KemPharm Filed Regulatory Application For ADHD Drug KemPharm Inc (NASDAQ: KMPH) said it has submitted a NDA for KP415, its investigational asset to treat attention deficit hyperactivity disorder, or ADHD. KP415 contains serdexmethylphenidate and KemPharm's prodrug d-methylphenidate.The stock jumped 37.61% to 45 cents in after-hours trading.CanFite Submits Safety Report Showing Favorable Safety Snd Risk-Benefit Ratios CAN FITE BIOPHARMA ADR REP 30 ORD (NYSE: CANF) announced submission of annual Drug Safety Update Reports to health regulatory agencies concerning Piclidenoson and Namodenoson, which show both investigational-stage drugs have favorable safety profiles and risk-benefit ratios in more than 1,500 patients.In premarket trading Tuesday, the shares were surging up 29.92% to $1.65.Thermo Fisher To Buy Qiagen For $10B In Cash Thermo Fisher Scientific Inc. (NYSE: TMO) announced a deal to buy molecular diagnostics company Qiagen NV (NYSE: QGEN) for 39 euros per share in cash or 9 billion euros ($10 billion).In premarket trading Tuesday, Qiagen shares were rallying 16.06% to $41.92 and Thermo Fisher shares were moving up 3.26% to $314.90,Alnylam Says Inherited Liver Enzyme Deficiency Drug Approved In Europe Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) said the European Commission has granted marketing authorization for GIVLAARI, an injection for subcutaneous use targeting aminolevulinic acid synthase 1 for the treatment of acute hepatic porphyria in adults and adolescents aged 12 years and olderLily Assuages COVID-19 Concerns Eli Lilly And Co (NYSE: LLY) issued an update alleviating any potential impact from COVID-19, stating that it does not anticipate shortages for any of its products, including all forms of insulin. It also said it does not source any of its approved medicines from China, and that its insulin manufacturing sites in the United States and Europe have not been impacted by coronavirus.View more earnings on IBBIn pre-market trading Tuesday, the shares were adding 0.87% to $134 .Earnings Omeros Corporation's (NASDAQ: OMER) fourth-quarter revenues rose 12% to $33.4 million and the net loss widened from 48 cents per share to 58 cents per share.The stock added 17% to $14.73 in after-hours trading.Zogenix, Inc. (NASDAQ: ZGNX) reported fourth-quarter revenues of $1.95 million compared to no revenues a year ago. The net loss per share widened from 53 cents to $1.26. Analysts estimated a loss of $1.06 per share.The stock slipped 6.93% to $23.50 in after-hours trading.Precigen reported fourth-quarter revenues of $17 million, sharply lower than $41.19 million a year ago. The net loss, however, narrowed from $2.59 per share to $1.09 per share. Analysts expected a loss of 27 cents per share on 23.4 million.The stock declined 7.93% to $3.60 in after-hours trading.Offerings Close on the heels of reporting positive late-stage data for selinexor, Karyopharm announced the commencement of a registered underwritten public offering of $150 million worth of its common shares.The stock moved down 6.17% to $26.01 in after-hours trading.On The Radar Earnings * Antares Pharma Inc (NASDAQ: ATRS) (before the market open) * Autolus Therapeutics Ltd - ADR (NASDAQ: AUTL) (before the market open) * Neuronetics Inc (NASDAQ: STIM) (before the market open) * TG Therapeutics Inc common stock (NASDAQ: TGTX) (before the market open) * Sierra Oncology Inc (NASDAQ: SRRA) (before the market open) * Infinity Pharmaceuticals Inc. (NASDAQ: INFI) (after the close) * Syndax Pharmaceuticals Inc (NASDAQ: SNDX) (after the close) * VIVUS, Inc. (NASDAQ: VVUS) (after the close) * Voyager Therapeutics Inc (NASDAQ: VYGR) (after the close) * DURECT Corporation (NASDAQ: DRRX) (after the close) * Cytokinetics, Inc. (NASDAQ: CYTK) (after the close)See more from Benzinga * Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates * The Week Ahead In Biotech: COVID-19 Stocks In The Spotlight, Earnings Taper Off * The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Did Changing Sentiment Drive Unity Biotechnology's (NASDAQ:UBX) Share Price Down By 45%?
    Simply Wall St.

    Did Changing Sentiment Drive Unity Biotechnology's (NASDAQ:UBX) Share Price Down By 45%?

    The simplest way to benefit from a rising market is to buy an index fund. When you buy individual stocks, you can make...

  • Here is What Hedge Funds Think About Unity Biotechnology, Inc. (NUBX)
    Insider Monkey

    Here is What Hedge Funds Think About Unity Biotechnology, Inc. (NUBX)

    It is already common knowledge that individual investors do not usually have the necessary resources and abilities to properly research an investment opportunity. As a result, most investors pick their illusory “winners” by making a superficial analysis and research that leads to poor performance on aggregate. Since stock returns aren't usually symmetrically distributed and index […]

  • Unity Biotechnology, Inc. (UBX) Is Burning These Hedge Funds
    Insider Monkey

    Unity Biotechnology, Inc. (UBX) Is Burning These Hedge Funds

    The elite funds run by legendary investors such as David Tepper and Dan Loeb make hundreds of millions of dollars for themselves and their investors by spending enormous resources doing research on small cap stocks that big investment banks don't follow. Because of their pay structures, they have strong incentives to do the research necessary […]

  • We're Keeping An Eye On Unity Biotechnology's (NASDAQ:UBX) Cash Burn Rate
    Simply Wall St.

    We're Keeping An Eye On Unity Biotechnology's (NASDAQ:UBX) Cash Burn Rate

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

  • Did You Manage To Avoid Unity Biotechnology's (NASDAQ:UBX) Painful 66% Share Price Drop?
    Simply Wall St.

    Did You Manage To Avoid Unity Biotechnology's (NASDAQ:UBX) Painful 66% Share Price Drop?

    Investing in stocks comes with the risk that the share price will fall. Unfortunately, shareholders of Unity...

  • Unity Biotech: Buy at the Low?
    Motley Fool

    Unity Biotech: Buy at the Low?

    Shares have been mired in a nearly continuous slide for the last year. Is Wall Street's pessimism misplaced?

  • Here's Why Unity Biotechnology Dropped as Much as 20.4% Today
    Motley Fool

    Here's Why Unity Biotechnology Dropped as Much as 20.4% Today

    The longevity-focused biopharma delivered mixed results in its first clinical trial in humans.